Get started
Travere Therapeutics, Inc. 2.25% 01-MAR-2029Travere Therapeutics, Inc. 2.25% 01-MAR-2029Travere Therapeutics, Inc. 2.25% 01-MAR-2029

Travere Therapeutics, Inc. 2.25% 01-MAR-2029

No trades
See on Supercharts
Overview
Analysis News

RTRX5376243 chart


Full chart

Key terms


Outstanding amount
‪316.25 M‬ USD
Face value
1,000.00 USD
Minimum denomination
1,000.00 USD
Coupon
2.25% (Fixed)
Coupon frequency
Semi-annual
Yield to maturity
0.67%
Maturity date
Mar 1, 2029
Term to maturity
3 years

About Travere Therapeutics, Inc. 2.25% 01-MAR-2029


Issuer
Travere Therapeutics, Inc.
Sector
Health Technology
Industry
Pharmaceuticals: Major
Home page
travere.com
Issue date
Mar 11, 2022
FIGI
BBG015WHCWR1
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

RTRX5376243 analysis


Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.

RTRX5376243 news



Dive into corporate with bonds that match in maturity and industry.